<DOC>
	<DOCNO>NCT02012153</DOCNO>
	<brief_summary>The general aim present study test cell therapy autologous ex-vivo expand mesenchymal stromal cell ( MSCs ) strategy induce tolerance living-donor kidney transplant recipient . MSCs prepare accordingly establish protocol , start bone marrow explants living-donor kidney transplant recipient obtain 3-4 month kidney transplant . From sample , MSCs expand Good Manufacturing Practice ( GMP ) approve facility use present study patient undergo kidney transplantation .</brief_summary>
	<brief_title>Mesenchymal Stromal Cells Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<criteria>Male female patient ; Aged 18 older ; Livingdonor ( relate unrelated , spouse/husband ) kidney transplant recipient ; NonHuman Leukocyte Antigen ( HLA ) identical donor ( one two haplotype mismatch ) ; First kidney transplant ; Capable understand purpose risk study ; Written inform consent . MSC donor positive HIV1 , HIV2 , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , syphilis ; Specific contraindication MSC infusion ; Any clinical relevant condition might affect study participation and/or study result ; Pregnant woman nurse mother ; Unwillingness inability follow study protocol investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mesenchymal stromal cell</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Tolerance</keyword>
</DOC>